Advanced gastric cancer: A disease of diverse clinical biology

Gastrointestinal Cancer Research

Volumn 3, Issue 3, 2009, Pages 125-126

  Jiang, Yixing ^a  

^a PENN STATE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; BEVACIZUMAB; CAPECITABINE; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; IRINOTECAN;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; EDITORIAL; HUMAN; PROTEIN EXPRESSION; STOMACH CANCER;

EID: 77953455011     PISSN: 19347820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (18)

1. Roder DM: The epidemiology of gastric cancer. Gastric Cancer 5(suppl 1):5-11, 2002
2. Blot WJ, Devesa SS, Kneller RW, et al: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265:1287-1289, 1991
3. Alberts SR, Cervantes A, van de Velde CJ: Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 14(suppl 2):31-36, 2003
4. Lagaly R, Horak A, Lee JH, et al: Patient with advanced gastric cancer responds twice to the same systemic therapy. Gastrointest Cancer Res 3:115-117, 2009
5. Webb A, Cunningham D, Scarffe JH, et al: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261-267, 1997
6. Ajani JA, Moiseyenko VM, Tjulandin S, et al: Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 25:3205-3209, 2007
7. Cunningham D, Rao M, Starling N, et al: Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesopha gogastric (OG) cancer: The REAL 2 Trial. Journal of Clinical Oncology. 2006 ASCO Annual Meeting Proceedings J Clin Oncol 24:18S, 2006 (abstr LBA4017)
8. Okines AF, Norman AR, McCloud P, et al: Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol [Epub ahead of print] 2009 May 27
9. Oh SY, Kwon HC, Seo BG, et al: A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer. Acta Oncol 46:336-341, 2007
10. Park YH, Lee JL, Ryoo BY, et al: Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer. Cancer Chemother Pharmacol 61:623-629, 2008
11. Damstrup L, Wedervang K, Hansen H: Carboplatin, capecitabine and docetaxel (CaCD) in patients with advanced gastric or gastro-esophageal (GE) adenocarcinoma. A single institutional experience. Ann Oncol 15:235-236, 2004 (abstr 895P)
12. Boku N, Yamamoto S, Shirao K, et al: Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S1 in advanced gastric cancer (JCOG 9912). 2007 ASCO Annual Meeting Proceedings J Clin Oncol 25:18S, 2007: (abstr LBA4513)
13. Chin K, Iishi H, Imamura H, et al: Irinotecan plus S-1 (IRIS) versus S-1 alone as first line treatment for advanced gastric cancer: Preliminary results of a randomized phase III study (GC0301/TOP-002). 2007 ASCO Annual Meeting Proceedings J Clin Oncol 25:18S, 2007 (abstr LBA4525)
14. Kelsen D, Jhawer M, Ilson D, et al: Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: results of a phase II clinical trial. 2009 ASCO Annual Meeting Proceedings J Clin Oncol 27:15s, 2009 (abstr 4512)
15. Yamada Y, Yamamoto S, Ohtsu A, et al: Impact of dihydropyrimidine dehydrogenase status of biopsy specimens on efficacy of irinotecan plus cisplatin, S-1, or 5-FU as first-line treatment of advanced gastric cancer patients in JCOG9912. 2009 ASCO Annual Meeting Proceedings J Clin Oncol 27:15s, 2009 (abstr 4535)
16. Ajani JA, Rodriquez W, Bodoky G, et al: Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): secondary and subset analyses. 2009 ASCO Annual Meeting Proceedings J Clin Oncol 27:15s, 2009 (abstr 4511)
17. Yoon HH, Powell M, Murphy K, et al: Outcome prediction based on single nucleotide polymorphisms (SNPs) in DNA repair paths in patients (pts) with esophageal adenocarcinoma (EAC) treated with preoperative (preop) cisplatin (C)-based chemoradiation (CRT): Results from the Eastern Cooperative Oncology Group (ECOG). 2009 ASCO Annual Meeting Proceedings J Clin Oncol 27:15s, 2009 (abstr 4530)
18. Van Cutsem E, Kang Y, Chung H, et al: Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). 2009 ASCO Annual Meeting Proceedings J Clin Oncol 27:15s, 2009 (abstr LBA4509)